External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

Krishna Institute of Medical Sciences (KIMS IN)

<ul><li>Operational Performance: Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%.</li><li>However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25, supported by new bed additions, a better case mix, and revised pricing through TPA negotiations. </li><li>Margins and Profitability: EBITDA margins remained stable at 24.8% YoY but declined 61bps QoQ due to lower OPEX. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Operational Performance: Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%.However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25, supported by new bed additions, a better case mix, and revised pricing through TPA negotiations. Margins and Profitability: EBITDA margins remained stable at 24.8% YoY but declined 61bps QoQ due to lower OPEX. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Growth to Be Driven by ARPOB